The immunoglobulin A (IgA) vasculitis market — treatments for a systemic small-vessel vasculitis formerly known as Henoch-Schönlein purpura, characterized by palpable purpura, joint pain, gastrointestinal symptoms, and potentially serious kidney involvement — remains anchored by generic corticosteroids and repurposed immunosuppressants rather than any disease-specific approved...